申请人:Takeda Pharmaceutical Company Limited
公开号:EP2128163A1
公开(公告)日:2009-12-02
The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy.
The present invention provides a compound represented by the formula (I):
wherein
R1 is a hydrogen atom or a substituent;
ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle;
ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and
ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted,
or a salt thereof.
本发明旨在提供一种具有乙酰辅酶A羧化酶(ACC)抑制作用的化合物,该化合物对于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症、癌症等具有卓越疗效。
本发明提供一种由以下式(I)表示的化合物:
其中
R1是氢原子或取代基;
环P是可选择取代的含氮芳香杂环;
环Q是可选择进一步取代的5-至7-成员的含氮非芳香杂环;和
环R是可选择融合的5-至7-成员的非芳香环,进一步可选择取代,
或其盐。